TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06545214

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Auditory stimulus
Description: Two auditory stimulus tests will be carried out during the patient's sleep. Using headphones, the investigator will administer auditory stimuli at regular, progressively louder intervals to determine the ability of the patient/ healthy subject to awaken to an auditory stimulus.

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaires
Description: Questionnaire to assess caffeine consumption habits Quality of life questionnaires QOLIE-31 Anxiety and depression questionnaires HADS

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaires
Description: Questionnaire to assess caffeine consumption habits Quality of life questionnaires QOLIE-31 Anxiety and depression questionnaires HADS
Study: NCT05211882

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immediate ENABLE nurse coaching, on top of usual care
Description: Participants in the intervention arm will start on the ENABLE program at point of randomization

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Participants on wait-list will continue on usual care and only start ENABLE 6 months after randomization.
Study: NCT06141187

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vertebroplasty
Description: PVP

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Vertebroplasty
Description: Sham PVP
Study: NCT04826068

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Emotional Processing
Description: Processing Emotions of others based on photographs of faces

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Processing
Description: Processing Emotions of others based on photographs of faces
Study: NCT06076369

Intervention type: PROCEDURE
Intervention: The tubular adenoma group
Description: Biopsy or removal of polyps for pathological examination. Collect baseline data such as gender, age, BMI, etc. If the pathology confirms a pure tubular adenoma, the observed object will be included in the group for final comparative analysis.
Study: NCT05445531

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Low-field magnetic resonance imaging
Description: Functional and morphologic imaging of the lungs

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Low-field magnetic resonance imaging
Description: Functional and morphologic imaging of the lungs

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Low-field magnetic resonance imaging
Description: Functional and morphologic imaging of the lungs

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Nailfold capillaroscopy
Description: Imaging of nailfold microvasculature

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Nailfold capillaroscopy
Description: Imaging of nailfold microvasculature

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Nailfold capillaroscopy
Description: Imaging of nailfold microvasculature
Study: NCT05928819

Intervention type: PROCEDURE
Intervention: Evaluation of the proportion of gastric neoplastic lesions detected by a computer-aided diagnosis system (CADx) compared with experienced endoscopists.
Description: Evaluation of the proportion of gastric neoplastic lesions detected by a computer-aided diagnosis system (CADx) compared with experienced endoscopists.
Study: NCT05445531

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Spiroergometry
Description: Cardiopulmonary exercise testing
Study: NCT05286632

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KidneYou APP
Description: KidneYou is a medical device designed to deliver digital therapy (DT) to patients. The DT utilizes high quality digital technologies to stimulate lifestyle changes in patients. KidneYou has been set up to improve the commitment of patients in following therapeutic directives (i.e. nutritional programs, daily/weekly physical activities) to manage their chronic diseases like CKD. Moreover, KidneYou can improve patient's awareness about his/her disease (mindfulness) so as to increase the individual human ability to be fully present at the ongoing disease's condition and react to it in active and positive manner. Particularly, the mindfulness program contained in this App has been designed to increase the patient's psychological and mental health, aiming at decreasing the perceived stress due to the underlying disease and to the attempts of life-style changes (i.e., healthy diet and physical activity) which may initially negatively affect the subject's natural attitudes.
Study: NCT05149313

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Lebrikizumab solution for injection administered subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lebrikizumab-matching Placebo
Description: Matching Placebo solution for injection administered subcutaneously.
Study: NCT05800977

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prizloncabtagene autoleucel
Description: Prizlon-cel is a novel 2nd generation 4-1BB bispecific chimeric antigen receptor T-cell (CAR-T) targeting both CD19 and CD20 antigens
Study: NCT06129370

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard practice
Description: Lexicomp and manual calculator
Study: NCT06030635

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Measurement of compartment compressibility using the CPMX1 device
Description: Patients will be monitored about every hour (+/- 30 min) for a total of 8 hours. Measurement time might be extended in case the patient undergoes trauma-related surgery during the measurement period and/or in case measurements are spaced further apart. Remaining measurements will be completed after the surgery. At each time point, three measurements of compartment compressibility will be conducted using the CMPX1 on both the affected (potential ACS) and healthy limb.
Study: NCT05445531

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Spiroergometry
Description: Cardiopulmonary exercise testing
Study: NCT06129370

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard practice
Description: Lexicomp and manual calculator

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medication dosing software
Description: Medication dosing software

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medication dosing software
Description: Medication dosing software
Study: NCT05742672

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ABDOMINAL MASSAGE APPLICATION
Description: * Experiment group twice a day in the morning and evening and 30 minutes after the feeding meal, for 15 minutes. For a period of time, effusion, petrissage, vibration massage movements will be applied by the researcher in accordance with the procedure (Abdominal Massage Application Directive). The application will continue for 7 days.- On the 3rd day (short term), 5th day (mid term) and 7th day (long term) to the massaged experimental group, the Constipation Severity Scale (CQS) and the Constipation Quality of Life Scale (QQQL) will be administered to determine the effect.~* Day 7 Rome Ш Constipation Diagnostic Criteria (Annex: 2) will be applied again and the patient's constipation status will be evaluated for the last time.~* Routine treatment and care practices in the clinic will continue.
Study: NCT04907006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-004 capsule
Description: After fasting for 10 hours, subjects in group 1 took one SY-004 (80mg) orally on an empty stomach on the day of administration with 240ml warm water; Subjects in group 2 began to eat high-fat breakfast 30 minutes before administration , and took one SY-004 capsule（80mg） orally with 240ml warm water. The subjects in both groups were fasted within 4 hours after taking the medicine, and drinking water was forbidden within 1 hour before and after taking SY-004.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-004 capsule
Description: After fasting for 10 hours, subjects in group 1 took one SY-004 (80mg) orally on an empty stomach on the day of administration with 240ml warm water; Subjects in group 2 began to eat high-fat breakfast 30 minutes before administration , and took one SY-004 capsule（80mg） orally with 240ml warm water. The subjects in both groups were fasted within 4 hours after taking the medicine, and drinking water was forbidden within 1 hour before and after taking SY-004.
Study: NCT05445531

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Spiroergometry
Description: Cardiopulmonary exercise testing

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Realtime deformability cytometry
Description: High-throughput measurement of cell deformability and physical properties

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Realtime deformability cytometry
Description: High-throughput measurement of cell deformability and physical properties

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Realtime deformability cytometry
Description: High-throughput measurement of cell deformability and physical properties
Study: NCT05431517

Intervention type: PROCEDURE
Intervention: Analysis of ERCP records
Description: Data will be extracted from ERCP records of stenting, mainly including: 1) Age at the time of ERCP; 2) Gender; 3) Indication; 4) Papilla selection (major or minor); 5) Whether endoscopic sphincterotomy (EST) was performed; 6) Presence of nipple diverticulum; 7) Morphology of the pancreatic duct; 8) Status of pancreatic duct stones; 9) Number, shape, material, diameter and length of the stent; and 10) Operation of the bile duct. Additional data were extracted from the pertinent ERCP records of stent migration: 1) Shape, material, diameter and length of the displaced stent; 2) Type of migration; and 3) Removal tools.

Intervention type: PROCEDURE
Intervention: Analysis of ERCP records
Description: Data will be extracted from ERCP records of stenting, mainly including: 1) Age at the time of ERCP; 2) Gender; 3) Indication; 4) Papilla selection (major or minor); 5) Whether endoscopic sphincterotomy (EST) was performed; 6) Presence of nipple diverticulum; 7) Morphology of the pancreatic duct; 8) Status of pancreatic duct stones; 9) Number, shape, material, diameter and length of the stent; and 10) Operation of the bile duct. Additional data were extracted from the pertinent ERCP records of stent migration: 1) Shape, material, diameter and length of the displaced stent; 2) Type of migration; and 3) Removal tools.
Study: NCT06139679

Intervention type: PROCEDURE
Intervention: ASD closure with fenestrated/non-fenestrated patch
Description: A PTFE patch is used to surgically close the interatrial defect. If closure with fenestrated patch is deemed necessary, a small opening is created on the patch

Intervention type: PROCEDURE
Intervention: ASD closure with fenestrated/non-fenestrated patch
Description: A PTFE patch is used to surgically close the interatrial defect. If closure with fenestrated patch is deemed necessary, a small opening is created on the patch
Study: NCT05621824

Intervention type: DEVICE
Intervention: Endoscopic ultrasound
Description: Use endoscopic ultrasound to examine the pancreatic lesions.

Intervention type: DEVICE
Intervention: Endoscopic ultrasound
Description: Use endoscopic ultrasound to examine the pancreatic lesions.

Intervention type: PROCEDURE
Intervention: EUS-Fine needle aspiration
Description: If solid mass of pancreas was found during EUS, EUS-FNA shall be conducted for diagnosis.

Intervention type: PROCEDURE
Intervention: EUS-Fine needle aspiration
Description: If solid mass of pancreas was found during EUS, EUS-FNA shall be conducted for diagnosis.
Study: NCT05618496

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sodium Hyaluronate Lyophilizate
Description: Device is placed directly onto the treated wound. The wound should be cleaned with antiseptic solution prior to the device administration. The device is fixed on the wound by secondary dressing: e.g. plaster, compression.
Study: NCT06033339

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling
Description: Collection of 10 ml of blood on EDTA tubes per patient. Once collected, the blood tubes will be transported within 24 hours to the IRB (Biotherapy Research Institute) of Montpellier University Hospital, where the monocytes will be isolated by magnetic sorting on the basis of expression of surface marker CD14+, after a preliminary step of Ficoll. Monocytes will then be frozen in nitrogen at -196°C until use (biobank).Gain-of-function experiments will then be performed on monocytes by transfecting them with the microRNA of interest or control. The expression of the pyrin protein and its phosphorylation rate will be evaluated after induction by immunoprecipitation experiments followed by western blot. The activity of the pyrin inflammasome will also be studied by looking at pyroptosis and toxicity rate using LDH test. All these experiments will be carried out in the absence and in the presence of the microRNA in order to study its role in the pathophysiology of FMF.
Study: NCT05951348

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping for 30 seconds
Description: waiting for 30 seconds after delivery of the fetus or milking of the cord in the direction of the fetus 10 times in time frame 10-15 seconds

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping for 30 seconds
Description: waiting for 30 seconds after delivery of the fetus or milking of the cord in the direction of the fetus 10 times in time frame 10-15 seconds
Study: NCT05745402

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobility Checkup for older adults
Description: The Mobility Checkup (MC) for older adults is a 45-minute preventative physical therapy visit designed to maintain mobility during aging. It has two parts, measurement (25 minutes) and education (20 minutes). The 5 standardized measures of physical performance in the MC are Walking speed, single leg stance time (balance), Five rep sit to stand (muscular endurance, transitions), 6-meter walk test (general endurance), and Timed up from floor test (transitions). Participants are provided education structured into 4 elements. 1. They are told their performance scores 2. They are shown how their performance scores on each of the measures compare to age and sex-referenced normative values 3. They are provided information about what their performance predicts about their health 4. They are referred to an appropriate provider if there was a health or safety concern during their MC or they are educated to follow the recommendations for physical activity that are recommended by the CDC.
Study: NCT05667727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nebulized epinephrine
Description: we are using 1:1000 epinephrine into nebulization form

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salbutamol
Description: Patient will receive salbutamol as 4th nebulization.
Study: NCT06053242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CELZ-201-DDT
Description: Subjects enrolled in the trial will receive CELZ-201-DDT at the specified dose into the lumbar paraspinal musculature. Each subject will receive a total of six injections, three injections on each side, under direct ultrasound guidance.
Study: NCT05665959

Intervention type: OTHER
Intervention: Reiki
Description: Reiki is based on the belief that disease occurs when an energy center is blocked, and that the energy is transmitted through touch. In distant Reiki, Reiki practitioners followed the traditional Usui Reiki protocol for distant healing.
Study: NCT06053242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CELZ-201-DDT
Description: Subjects enrolled in the trial will receive CELZ-201-DDT at the specified dose into the lumbar paraspinal musculature. Each subject will receive a total of six injections, three injections on each side, under direct ultrasound guidance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CELZ-201-DDT
Description: Subjects enrolled in the trial will receive CELZ-201-DDT at the specified dose into the lumbar paraspinal musculature. Each subject will receive a total of six injections, three injections on each side, under direct ultrasound guidance.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive a placbeo injection into the lumbar paraspinal musculature. Each subject will receive a total of six injections, three injections on each side, under direct ultrasound guidance.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive a placbeo injection into the lumbar paraspinal musculature. Each subject will receive a total of six injections, three injections on each side, under direct ultrasound guidance.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive a placbeo injection into the lumbar paraspinal musculature. Each subject will receive a total of six injections, three injections on each side, under direct ultrasound guidance.
Study: NCT04994977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given at 0.5 mg/ml.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given at 5 mg/ml.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Given at 0.2 mg/ml.
Study: NCT05572294

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation, breathing exercises (including incentive spirometry), and yoga therapy
Description: Sickle cell patients admitted with a vaso-occlusive pain crisis over a consecutive 12-week period will be offered participation in the study. After providing informed consent, participants will have access to 4 videos containing guided mindfulness meditation, breathing exercises, and gentle yoga therapy. The videos are 5-12 minutes long and taught by a physical therapist who is also certified in yoga therapy. Participants may turn off the video at any time. Participants will have access to the videos for the duration of their hospitalization, and they may watch the videos as many times as they desire.
Study: NCT04958486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Azacytidine and trastuzumab infusion
Description: Patients will receive once weekly 10 mg intraventricular 5-Azacytidine infusions for six consecutive weeks followed by observation in the infusion suite for a minimum of 30 minutes and once weekly 21 mg intraventricular trastuzumab infusions for six consecutive weeks followed by observation for a minimum of 2 hour after each infusion for the first 2 infusions. During this monitoring period, temperature, blood pressure, heart rate, and oxygen saturation will be measured. Patients will also have a neurological examination performed to observe for neurological changes. All patients will undergo an MRI of the brain and total spine with and without gadolinium within 7 days after the final 5-AZA and trastuzumab infusion to determine treatment response and to assess for any signal changes in the brain or spine caused by the infusions and they will have a 30 day and a 90 day follow-up assessment by telephone or in person for assessment of outcome measures and safety
Study: NCT04736849

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous epidural and dorsal root stimulation
Description: Abbott percutaneous trial lead for dorsal root ganglion neurostimulation (Model MN10350)~Abbott percutaneous trial lead for epidural neurostimulation (Model 3086)~Abbott clinician programmer for epidural and dorsal root ganglion neurostimulation (Model 3874)~Ripple Neuromed Nomad Neurostimulation System
Study: NCT05518916

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nonfarmacology method
Description: Yakson Method and Swaddling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nonfarmacology method
Description: Yakson Method and Swaddling
Study: NCT06562985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY3018250 Dose 1
Description: Infusion, single dose
Study: NCT05647044

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: intermittent theta burst stimulation
Description: intermittent theta burst stimulation (iTBS) will be delivered with the Magventure MagProX100 with MagOption stimulation and Magpro Cool Coil B65 A/P. The Magpro Cool Coil B65 A/P can be switched to active or placebo. The Magventure C-B60 coil will be used to deliver single TMS pulses for motor threshold determination.
Study: NCT06562985

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: BAY3018250 matching placebo, infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: BAY3018250 matching placebo, injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY3018250 Dose 2 infusion
Description: Infusion, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY3018250 Dose 2 injection
Description: Injection, single dose
Study: NCT05862636

Intervention type: BEHAVIORAL
Intervention: Mindfulness Training
Description: All participants will follow a mindfulness course consisting of group sessions of 2-3h duration that are organized (nearly) weekly and are spread over a period of eight weeks. The specific timeline and organisation of the course may differ between the participating sites but all courses will involve a comparable amount of contact hours with the mindfulness trainer. Each session consists of guided experiential mindfulness exercises (e.g., body scan, breathing space, breath focus, walk meditation), sharing of experiences of these exercises, reflections in small groups, psychoeducation, and review of home practices.~The mindfulness courses are based on one of the two most well-known MBIs, Mindfulness-Based Cognitive Therapy (Segal et al., 2002) and Mindfulness-Based Stress Reduction (Kabat-Zinn, 1990), or a combination thereof. Courses follow a standardised protocol with group sessions and daily homework tasks taught by experienced and certified mindfulness trainers.

Intervention type: BEHAVIORAL
Intervention: Mindfulness Training
Description: All participants will follow a mindfulness course consisting of group sessions of 2-3h duration that are organized (nearly) weekly and are spread over a period of eight weeks. The specific timeline and organisation of the course may differ between the participating sites but all courses will involve a comparable amount of contact hours with the mindfulness trainer. Each session consists of guided experiential mindfulness exercises (e.g., body scan, breathing space, breath focus, walk meditation), sharing of experiences of these exercises, reflections in small groups, psychoeducation, and review of home practices.~The mindfulness courses are based on one of the two most well-known MBIs, Mindfulness-Based Cognitive Therapy (Segal et al., 2002) and Mindfulness-Based Stress Reduction (Kabat-Zinn, 1990), or a combination thereof. Courses follow a standardised protocol with group sessions and daily homework tasks taught by experienced and certified mindfulness trainers.